LABT: LABT to Present June 25 on Nu-3, Plans for Phase 2 in Infected Diabetic Foot Ulcers

AI Summary

Lakewood-Amedex (NASDAQ: LABT) said CEO Kelvin Cooper will present at the Life Sciences Virtual Investor Forum on June 25 to outline the company's growth strategy and its lead candidate Nu-3, a topical gel being developed for infected diabetic foot ulcers (iDFU). The company said it intends to advance Nu-3 into Phase 2 trials and highlighted its Bisphosphocin® platform as a fast-acting, broad‑spectrum antimicrobial that targets resistant pathogens (e.g., MRSA, VRE); the release contains no new trial data and timing remains forward-looking.

Positives

CEO presentation scheduled for June 25 at the Life Sciences Virtual Investor Forum
Lead candidate Nu-3 is positioned to advance into Phase 2 for infected diabetic foot ulcers
Bisphosphocin® platform described as fast-acting, broad-spectrum and active vs. resistant strains including MRSA and VRE

Negatives

No clinical efficacy or safety data disclosed in this announcement
Phase 2 timing and regulatory path are forward‑looking and not specified
Statements subject to usual clinical, regulatory and financing risks